Literature DB >> 22565048

Identification and isolation of slow-dividing cells in human glioblastoma using carboxy fluorescein succinimidyl ester (CFSE).

Loic P Deleyrolle1, Mark R Rohaus, Jeff M Fortin, Brent A Reynolds, Hassan Azari.   

Abstract

Tumor heterogeneity represents a fundamental feature supporting tumor robustness and presents a central obstacle to the development of therapeutic strategies(1). To overcome the issue of tumor heterogeneity, it is essential to develop assays and tools enabling phenotypic, (epi)genetic and functional identification and characterization of tumor subpopulations that drive specific disease pathologies and represent clinically relevant targets. It is now well established that tumors exhibit distinct sub-fractions of cells with different frequencies of cell division, and that the functional criteria of being slow cycling is positively associated with tumor formation ability in several cancers including those of the brain, breast, skin and pancreas as well as leukemia(2-8). The fluorescent dye carboxyfluorescein succinimidyl ester (CFSE) has been used for tracking the division frequency of cells in vitro and in vivo in blood-borne tumors and solid tumors such as glioblastoma(2,7,8). The cell-permeant non-fluorescent pro-drug of CFSE is converted by intracellular esterases into a fluorescent compound, which is retained within cells by covalently binding to proteins through reaction of its succinimidyl moiety with intracellular amine groups to form stable amide bonds(9). The fluorescent dye is equally distributed between daughter cells upon divisions, leading to the halving of the fluorescence intensity with every cell division. This enables tracking of cell cycle frequency up to eight to ten rounds of division(10). CFSE retention capacity was used with brain tumor cells to identify and isolate a slow cycling subpopulation (top 5% dye-retaining cells) demonstrated to be enriched in cancer stem cell activity(2). This protocol describes the technique of staining cells with CFSE and the isolation of individual populations within a culture of human glioblastoma (GBM)-derived cells possessing differing division rates using flow cytometry(2). The technique has served to identify and isolate a brain tumor slow-cycling population of cells by virtue of their ability to retain the CFSE labeling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565048      PMCID: PMC3466660          DOI: 10.3791/3918

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  12 in total

Review 1.  Fluorescent dyes for lymphocyte migration and proliferation studies.

Authors:  C R Parish
Journal:  Immunol Cell Biol       Date:  1999-12       Impact factor: 5.126

Review 2.  Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

Authors:  A B Lyons
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

3.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

4.  Isolation and expansion of human glioblastoma multiforme tumor cells using the neurosphere assay.

Authors:  Hassan Azari; Sebastien Millette; Saeed Ansari; Maryam Rahman; Loic P Deleyrolle; Brent A Reynolds
Journal:  J Vis Exp       Date:  2011-10-30       Impact factor: 1.355

5.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

6.  Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.

Authors:  T L Holyoake; X Jiang; H G Jorgensen; S Graham; M J Alcorn; C Laird; A C Eaves; C J Eaves
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

Review 7.  The origins of cancer robustness and evolvability.

Authors:  Tianhai Tian; Sarah Olson; James M Whitacre; Angus Harding
Journal:  Integr Biol (Camb)       Date:  2010-10-14       Impact factor: 2.192

8.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

9.  Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.

Authors:  Jennifer L Dembinski; Stefan Krauss
Journal:  Clin Exp Metastasis       Date:  2009-05-07       Impact factor: 5.150

10.  Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide.

Authors:  Kannan Krishnamurthy; Guanghu Wang; Dmitriy Rokhfeld; Erhard Bieberich
Journal:  Breast Cancer Res       Date:  2008-12-16       Impact factor: 6.466

View more
  8 in total

1.  Time-lapse microscopic observation of non-dividing cells in cultured human osteosarcoma MG-63 cell line.

Authors:  John Dosch; Elise Hadley; Cal Wiese; Marissa Soderberg; Tori Houwman; Kai Ding; Alexandra Kharazova; John L Collins; Bart van Knippenberg; Carl Gregory; Alexander Kofman
Journal:  Cell Cycle       Date:  2017-12-26       Impact factor: 4.534

Review 2.  Strategies for isolating and enriching cancer stem cells: well begun is half done.

Authors:  Jiang-Jie Duan; Wen Qiu; Sen-Lin Xu; Bin Wang; Xian-Zong Ye; Yi-Fang Ping; Xia Zhang; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Stem Cells Dev       Date:  2013-05-09       Impact factor: 3.272

3.  ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.

Authors:  Kate Marie Lewis; Claudia Petritsch
Journal:  Transl Neurosci       Date:  2013-12       Impact factor: 1.757

4.  Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.

Authors:  Lan B Hoang-Minh; Florian A Siebzehnrubl; Changlin Yang; Silveli Suzuki-Hatano; Kyle Dajac; Tyler Loche; Nicholas Andrews; Michael Schmoll Massari; Jaimin Patel; Krisha Amin; Alvin Vuong; Ana Jimenez-Pascual; Paul Kubilis; Timothy J Garrett; Craig Moneypenny; Christina A Pacak; Jianping Huang; Elias J Sayour; Duane A Mitchell; Matthew R Sarkisian; Brent A Reynolds; Loic P Deleyrolle
Journal:  EMBO J       Date:  2018-10-15       Impact factor: 11.598

5.  Chromatin Remodeling Factor Brg1 Supports the Early Maintenance and Late Responsiveness of Nestin-Lineage Adult Neural Stem and Progenitor Cells.

Authors:  David Petrik; Sarah E Latchney; Irene Masiulis; Sanghee Yun; Zilai Zhang; Jiang I Wu; Amelia J Eisch
Journal:  Stem Cells       Date:  2015-10-09       Impact factor: 6.277

6.  NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer.

Authors:  Alexander J Cole; Mangala Iyengar; Santiago Panesso-Gómez; Patrick O'Hayer; Daniel Chan; Greg M Delgoffe; Katherine M Aird; Euisik Yoon; Shoumei Bai; Ronald J Buckanovich
Journal:  JCI Insight       Date:  2020-04-09

Review 7.  Lipid droplets: platforms with multiple functions in cancer hallmarks.

Authors:  André L S Cruz; Ester de A Barreto; Narayana P B Fazolini; João P B Viola; Patricia T Bozza
Journal:  Cell Death Dis       Date:  2020-02-06       Impact factor: 8.469

8.  Slow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem Cells.

Authors:  Changlin Yang; Guimei Tian; Mariana Dajac; Andria Doty; Shu Wang; Ji-Hyun Lee; Maryam Rahman; Jianping Huang; Brent A Reynolds; Matthew R Sarkisian; Duane Mitchell; Loic P Deleyrolle
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.